» Articles » PMID: 11728337

The Immunological Synapse of CTL Contains a Secretory Domain and Membrane Bridges

Overview
Journal Immunity
Publisher Cell Press
Date 2001 Dec 1
PMID 11728337
Citations 314
Authors
Affiliations
Soon will be listed here.
Abstract

Cytotoxic T lymphocytes (CTL) rapidly destroy their targets. Here we show that although target cell death occurs within 5 min of CTL-target cell contact, an immunological synapse similar to that seen in CD4 cells rapidly forms in CTL, with a ring of adhesion proteins surrounding an inner signaling molecule domain. Lytic granule secretion occurs in a separate domain within the adhesion ring, maintaining signaling protein organization during exocytosis. Live and fixed cell studies show target cell plasma membrane markers are transferred to the CTL as the cells separate. Electron microscopy reveals continuities forming membrane bridges between the CTL and target cell membranes, suggesting a possible mechanism for this transfer.

Citing Articles

Cellular polarity pilots breast cancer progression and immunosuppression.

Huang J, Luo S, Shen J, Lee M, Chen R, Ma S Oncogene. 2025; .

PMID: 40057606 DOI: 10.1038/s41388-025-03324-0.


Analysis of immune synapses by τau-STED imaging and 3D-quantitative colocalization of lytic granule markers.

Scharrig E, Sanmillan M, Giraudo C Methods Cell Biol. 2025; 193:1-13.

PMID: 39919838 PMC: 11806212. DOI: 10.1016/bs.mcb.2023.01.018.


The Golgi complex governs natural killer cell lytic granule positioning to promote directionality in cytotoxicity.

Pedroza L, van den Haak F, Frumovitz A, Hernandez E, Hegewisch-Solloa E, Orange T Cell Rep. 2025; 44(1):115156.

PMID: 39813120 PMC: 11844255. DOI: 10.1016/j.celrep.2024.115156.


A Thermo-responsive collapse system for controlling heterogeneous cell localization, ratio and interaction for three-dimensional solid tumor modeling.

Li Y, Orange J bioRxiv. 2025; .

PMID: 39764015 PMC: 11703237. DOI: 10.1101/2024.12.26.630018.


Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms.

Wu Y, Sun X, Kang K, Yang Y, Li H, Zhao A J Hematol Oncol. 2024; 17(1):106.

PMID: 39511607 PMC: 11542428. DOI: 10.1186/s13045-024-01621-x.